Zylpha Appoints Rachel Kitson To Drive Technical Sales
Leading legal systems innovator Zylpha (www.zylpha.com) has appointed Rachel Kitson as Technical Sales Consultant for…
Month: March 2021
OKI Europe’s C650 Wins Print IT Reseller’s Editor’s Choice Award
The world’s smallest high performance A4 colour printer tops the list in the publication’s annual…
Tableau Business Science Brings Powerful Data Science Capabilities to Business People
SEATTLE, March 23, 2021 /PRNewswire/ — Tableau, the world’s leading analytics platform (NYSE: CRM), today…
Biofidelity announces first peer reviewed publication of breakthrough ASPYRE™ technology
Publication validates the ability of ASPYRE to detect single copies of somatic variants in tissue…
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE
RECORDATI:  POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S…
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
Lead product candidate, ZB001, has first-in-class potential in China for Thyroid Eye Disease Rapidly advancing…
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People
— Collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic…
Does Your Mask/Respirator Filter Live Viruses?
For the First Time Scientific Data From a Certified Canadian Laboratory Answers This Fundamental Question….
Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone
Press Release Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone…
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS)…
Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency
With eight new configurations, cobas pro® integrated solutions offers labs greater flexibility to ramp up…
New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by…
Verrica Announces Pricing of Public Offering of Common Stock
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA),…
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to…
Bioasis Technologies Inc. Announces Warrant Extension and Repricing
NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the…
Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes
Company announcement – No. 16 / 2021 Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon)…
Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and…
Blood Sugar Blaster Reviews – Diabetes Supplement launched
Blood Sugar Blaster is a sugar-regulating supplement that seeks to prevent the user from catching…
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
EDISON, N.J., March 22, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical…
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and…